Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.
Thomas M CaparrottaAndrew M GreenhalghKaren OsinskiRobert M GiffordSvenja MoserSarah H WildRebecca M ReynoldsDavid J WebbHelen M ColhounPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
In T2D, SGLT2is appear safe from the CV perspective and may have associated benefit in primary as well as secondary CVD prevention. For safety, they may be associated with an increased risk of GMI, LLA and DKA, although longer follow-up studies are needed.